October 27, 2015

Generic Drug Product Development (ANDA) and Paragraph IV Filing Strategy

IndiaProduction

IndiaProduction

Recommended Reports

Clostridium difficile Toxin A (toxA or EC 3.4.22.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

Clostridium difficile Toxin B (toxB or EC 3.4.22.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

Plasminogen (Plasmin or PLG or EC 3.4.21.7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

Caspase (CASP or EC 3.4.22.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

Cytosolic Phospholipase A2 (Phospholipase A2 Group IVA or PLA2G4A or EC 3.1.1.4 or EC 3.1.1.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

View All

More

Medical Technology UK 2023

International congress on pediatrics neonatal and nursing care, Prague

Outsourcing in Clinical Trials: Medical Devices USA 2023

Outsourcing in Clinical Trials West Coast (& device stream) 2023